Thyroid Hormone Ratio and Lung Cancer Treatment Outcomes
Author Information
Author(s): Nelli Fabrizio, Ruggeri Enzo Maria, Schirripa Marta, Virtuoso Antonella, Giannarelli Diana, Raso Armando, Remotti Daniele, Fabbri Agnese
Primary Institution: Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, Viterbo, Italy
Hypothesis
Changes in the fT3/fT4 ratio could affect the survival outcomes of patients with advanced non-small cell lung cancer undergoing pembrolizumab-based therapies.
Conclusion
Patients with an increased fT3/fT4 ratio experienced a significantly decreased risk of disease progression and mortality during treatment.
Supporting Evidence
- Patients with a higher fT3/fT4 ratio after treatment had significantly better progression-free survival.
- The study included 258 patients, with 88 analyzed after propensity score matching.
- Dynamic changes in thyroid hormone levels were statistically significant after treatment.
- Patients with low fT3/fT4 ratios had worse overall survival outcomes.
Takeaway
This study found that the balance of thyroid hormones can help predict how well patients with lung cancer respond to treatment.
Methodology
The study analyzed data from patients with advanced NSCLC treated with pembrolizumab, comparing thyroid hormone ratios before and after treatment.
Potential Biases
Potential bias due to reliance on internal records for laboratory test results and the non-independent nature of radiological assessments.
Limitations
The study was retrospective and conducted at a single center, which may introduce selection bias.
Participant Demographics
Patients with advanced non-small cell lung cancer, predominantly male, with a mean age of 70 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 16.1–24.6 months
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website